ECR Minerals #ECR – Andrew Scott talks to CEO Andrew Haythorpe August 26, 2022 – Posted in: Blog

Andrew Scott talks to ECR CEO Andrew Haythorpe. They discuss the Bendigo property sale, upcoming drilling campaign at Blue Moon and delayed assay results from Bailieston. Andrew also provides an update on the 2nd drilling rig update, and talks about the initial exploration at Lolworth Range, which really is virgin territory. The interview finishes with a look forward, plus Andrew’s overview of what he sees as a dysfunctional #gold market

Continue reading

ECR Minerals #ECR – Andrew Scott talks to Andrew Haythorpe June 1, 2022 – Posted in: Blog

ECR Minerals CEO Andrew Haythorpe talks to Andrew Scott. Andrew discusses the reasons behind the appointment of Adam Jones – his technical knowledge and attention to detail which has resulted in some science based breakthroughs. Andrew says the board are looking at projects wider afield, and discusses the Danglay gold project in the Philippines before returning to Bailieston and the challenges created by the COVID driven assay delays. Andrew looks at Blue Moon, where there are…

Continue reading

Tiziana CEO Kunwar Shailubhai discusses the company’s anti il6 technology to deliver drugs to lungs with Andrew Scott at Proactive Investors May 6, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO and chief scientific officer Kunwar Shailubhai discusses the recent excitement around inhalation and the direct delivery of drugs to lungs. ”It makes a lot of sense”, he says. Shailubhai says he’s pleased he’s covered this approach in his recent patent and in fact was one of the first to do it . ”COVID-19 grows in lungs, that’s where it proliferates and produces inflammation .. that leads to what’s known as…

Continue reading

Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study March 12, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal. The data from the FLU-v 003 phase IIb study of the FLU-v vaccine appeared in the Annals of Internal Medicine periodical. Also this week hVIVO began…

Continue reading

Proactive Investors interview with the Open Orphan #ORPH team on its future and ‘the lottery ticket’ sitting within hVIVO February 4, 2020 – Posted in: Open Orphan (ORPH)

  Open Orphan PLC‘s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott following the completion last week of its £5.3mln fundraise. Also in studio is adviser to Open Orphan and founder of hVivo Professor John Oxford. Professor Oxford’s been a leader in the field of vaccine and anti-viral clinical trials for the last 20 years. hVivo, which has recently been acquired by Open Orphan, owns the largest commercial quarantine clinic in northern Europe and…

Continue reading